We are live on ! Find out more
CNTB icon

Connect Biopharma Holdings

17 hedge funds and large institutions have $2.45M invested in Connect Biopharma Holdings in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 17 → 17 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

1.49% less ownership

Funds ownership: 4.4% → 2.91% (-1.5%)

85% less capital inflows, than outflows

Capital inflows: $200K | Capital outflows: $1.36M

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
6
Increased
3
Reduced
3
Closed
6
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

CNTB Hedge Fund Activity: Q3 2025 in Review

17 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q3 2025, worth a combined $2.45M — up 2% from $2.4M a quarter earlier.

Fund positioning in CNTB was balanced in Q3 2025: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $103K. The largest seller was BML Capital Management, cutting an estimated $981K.

  • 17 institutional investors held Connect Biopharma Holdings (CNTB) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $2.45M of Connect Biopharma Holdings stock for Q3 2025, up 2% quarter-over-quarter.
  • 6 funds opened new Connect Biopharma Holdings positions in Q3 2025 and 6 closed out, a net change of 0 holders.
  • The largest Connect Biopharma Holdings buyer in Q3 2025 was Marshall Wace, an estimated $103K added.
  • The largest Connect Biopharma Holdings seller in Q3 2025 was BML Capital Management, an estimated $981K sold.

Based on aggregated 13F filings for Q3 2025.